Top Message

Stock Quotes

Latest Schedule of IR Events

IR Schedule

To our shareholders and investors

President Mitsuo Sawai

I would first like to thank all of our shareholders and investors for their continued support. On behalf of the new management elected at the 67th Annual Shareholders Meeting, I would also like to express my gratitude and offer a short message.
Since our foundation in 1929 and incorporation in 1948, the Company has been engaged in the manufacturing and sale of generic drugs that contribute to alleviating the burdens of patients and reducing medical expenses under a corporate philosophy of “Patients First,” with a mission to enable people to live healthy lives through pharmaceutical products made with sincerity and dedication.

On May 14, we released our new medium-term business management plan, “M1 TRUST 2018”, targeted three years from FY2015 to FY2017. We surpassed 100 billion yen mark in FY2014, the final year of M1 TRUST 2015. We target at net sales of 147 billion yen, operating profit of 25 billion yen and implementing stable distribution aimed at a dividend payout ratio of 30% in FY2017, the final year of “M1 TRUST 2018” by transforming into a “company that can continue to grow in the midst of rapidly changing market condition”.
We continue to devote ourselves to become a globally recognized generics company by steadily implementing our key strategies of “M1 TRUST 2018” contributing to medical expense reduction through generics and by surpassing the 200 billion yen mark of net sales.

We will continue our efforts to enhance corporate value, aiming to become an “indispensable company” to society, with all directors and employees working in a united effort. We would highly appreciate your continuous understanding and support.

June 2015
Mitsuo Sawai, President

Back to Top